Business
INVO Bioscience Announces First Joint-Venture Grand Opening Scheduled for August 9, 2021 in Birmingham, Alabama
Innovative Fertility Specialists, An INVO Center becomes the first JV-owned clinic focused on providing INVOcell to assist the underserved patients in need of
About this update from Invo Fertility, Inc.
[{"type":"text","content":"Innovative Fertility Specialists, An INVO Center becomes the first JV-owned clinic focused on providing INVOcell to assist the underserved patients in need of advanced fertility care\n\n\nSARASOTA, Fla., Aug. 2, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo culture system (IVC), INVOcell®, today announced the Company's first Joint Venture INVO Center practice in the United States, based in Birmingham, Alabama, will officially open on August 9, 2021. \n\n \n \n \n \n \n \n\n \nIn partnership with reproductive specialists Dr. Nicholas Cataldo, MD, MPH, Dr. Karen R. Hammond, DNP, CRNP, and Lisa Ray, MS, ELD, the new Birmingham practice, named \"Innovative Fertility Specialists, An INVO Center\" will provide fertility treatment utilizing the efficient, effective, and affordable INVOcell option. The practice will begin seeing patients upon opening in August and perform initial treatment cycles in the month of September 2021.\n\n Dr. Hammond commented, \"With the opening of the country's first INVOcell medical practice, we are advancing a core mission towards improving access to advanced fertility services for the many patients who would otherwise never have the opportunity. To date, we have already received numerous advanced inquiries via word of mouth and have dozens of patients scheduled for initial patient consultations who are eager to proceed with treatment. As we officially open the center next week, we expect to accelerate our marketing programs with the help of the INVO marketing team to enhance overall patient awareness around Innovative Fertility Specialists, An INVO Center.\"\n\n Steve Shum, CEO of INVO Bioscience, commented, \"This is an extremely exciting time for INVO, the fertility industry, and patients around the country as we near the grand opening of our first INVOcell Center in the United States. Drs. Cataldo, Hammond, and Ray have been leading advocates of the INVOcell procedure for many years and we are thrilled to have them as partners helping us to bring our fertility treatment option to patients. Our internal team has worked with a committed focus to develop this part of our strategy. The INVO Center approach creates a unique opportunity to help drive accelerated adoption of the INVOcell solution while also increasing mu...